Tool: Training Presentation: Clinical Research Responsibilities for NIDCR-Funded Investigators Purpose: To provide an overview of the key roles and responsibilities.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
IHV-Nigeria WAB-TP Health Research Ethics Committee Records and Reports Dr Oluyemisi Akinwande IHVN.
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
Quality Management within the Clinical Research Process
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
The Consent Process: It’s More Than Just a Form A “10 Minute Training” Brought to you by Cyndi Long, MS, RD, CCRC CU Sports Medicine.
Institutional Review Boards (IRBs), Informed Consent, and Responsibilities Requirement for IRBs -DHHS: 45 CFR Part 46 -FDA: 21 CFR 56 Requirement for and.
Good Clinical Practice in Research
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Tool Summary Sheet Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites. Tool: Training Presentation:
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
Tool Summary Sheet Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites. Tool: Sponsor Responsibilities.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Overview of Good Clinical Practices (GCPs)
Federalwide Assurance Presentation for IRB Members.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
“So You Think You Know GCP …” Session S794 Jill Matzat, RN, BSN, CCRA, CCRT President, Medical Research Management & CRA Solutions, Inc. Paul Below, CCRA,
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
The QA/QI Process Human Research Subjects Protection Human Investigation Committee Tracy Rightmer, JD, CIP Compliance Manager.
Privacy and Confidentiality. Definitions n Privacy - having control over the extent, timing, and circumstances of sharing oneself (physically, behaviorally,
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Human Subjects Research Office of Responsible Research Practices Human Subjects Research Vanessa Hill, MSHS, CCRC Senior Quality Improvement Specialist.
TUN IRB: The Basics February 26, IRB Function Review human-subject research Ensure the rights & welfare of human subjects are adequately protected.
Investigational Devices and Humanitarian Use Devices June 2007.
Sponsor Visits and Monitoring
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Informed Consent Presented by Marian Serge, RN. Goals Informed consent process and form Title 38 CFR , Common Rule required elements and additional.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Good Clinical Practice (GCP) and Monitoring Practices
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
Upcoming Changes to the Common Rule
MAINTAINING THE INVESTIGATOR’S SITE FILE
Investigator Responsibilities for Clinical Trials Research
Beverley Alberola, CIP Associate Director, Research Protections
Reportable Events & Other IRB Updates February 2017
Alyssa Speier, MS, CIP November 13, 2013
Regulatory Binder: Maintaining Essential Study Documentation
Elements of an Organized Regulatory Binder
Elements of a Successful Informed Consent
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Good Clinical Practice in Research
TRTO (Translational Research Trials Office)
Research with Human Subjects
Good clinical practice
Presentation transcript:

Tool: Training Presentation: Clinical Research Responsibilities for NIDCR-Funded Investigators Purpose: To provide an overview of the key roles and responsibilities of investigators and staff engaged in NIDCR-funded research. Audience/User:NIDCR study staff, including PIs, Sub-Is, and Site Study Coordinators Details: This training presentation includes Types of NIDCR Studies, Human Subjects Protection, Administrative and Regulatory Responsibilities, Research Planning and Considerations, and Documentation/Record Keeping. Speaker notes are provided for selected slides. Best Practice Recommendations:  Delete the slide containing this Tool Summary Sheet before presenting or providing this presentation to a study site.  Customize the amount and type of information that is provided verbally based on the type of study (e.g., interventional, observational), the experience level of study site personnel, and the time allotted for the presentation. Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites.

V NIDCR National Institute of Dental and Craniofacial Research National Institutes of Health CROMS C linical Research Operations and Management Support Rho, Inc., Federal Division

 Note that this is a general slide presentation designed for a broad audience of clinical researchers.  Accordingly, some sections may not apply to your protocol.  Information that may not be applicable for all studies is indicated via blue italics. 3

 Examples include references to: ◦ Investigational Product (IP), the Investigator’s Brochure (IB), or a study pharmacist ◦ Safety reporting and adverse events ◦ Randomization and unblinding procedures ◦ Regulatory authorities ◦ Clinical treatment (for a behavioral or study or a registry) 4

 Good Clinical Practice (GCP) Guidelines (ICH-E6) ◦ Widely accepted international research standards  Title 45 Code of Federal Regulations (CFR) Part 46 ◦ Applies to federally funded research ◦ Federal regulations to protect human subjects ◦ Subpart A: The Common Rule ◦ IRB roles and responsibilities/Informed Consent 5

 Clinical Trials involving a biomedical or behavioral intervention  Clinical Research Studies, including: ◦ Observational ◦ Specimen Collection ◦ Epidemiology or Surveillance studies 6

To review key roles and responsibilities of investigators and staff engaged in NIDCR-funded research  Human Subject Protection  Administrative and Regulatory Responsibilities  Research Planning and Considerations  Documentation and Record Keeping 7

8

 Required for human subjects research supported by DHHS  Must register IRB with OHRP/File FWA  Applications can be submitted online  Commitment to comply with 45 CFR Part 46 9

 Membership, functions, and operations  Initial and continuing review of research  Criteria for approval of research  Decisions regarding termination/suspension of study due to harm or noncompliance  Documentation and record keeping 10

 Know your IRB’s review schedule and process  Obtain/document IRB approval prior to initiating research  Obtain/document IRB approval prior to implementing any protocol amendments (administrative or otherwise)  Notify IRB regarding adverse events (AEs) and unanticipated problems (UPs) as required  Obtain and document IRB acknowledgement of study completion 11

 Obtain without coercion or undue influence  Language understood by subjects  Cannot contain language waiving subject’s legal rights  Cannot release institution from liability for negligence  Answer questions/allow time for consideration  Subjects must receive signed/dated copy of the consent document 12

 Statement that the study involves research  Statement that participation is voluntary  Information about purpose, duration, and procedures  Number of subjects involved in the study  Description of risks, benefits, and alternatives  Information about compensation/care for injury  Statement regarding confidentiality of records 13

 Description of possible unforeseen risks  Circumstances for termination without subject consent  Consequences of withdrawing from the study  Additional costs that may result from participation  Statement that new research findings will be shared  Contact information for questions/concerns 14

 Title 45 CFR Part 46; Subparts B, C, and D ◦ Subpart B: Additional protections for pregnant women, human fetuses, and neonates ◦ Subpart C: Additional protections for prisoners ◦ Subpart D: Additional protections for children 15

16

Investigators who are responsible for study conduct should:  Have appropriate education, experience, and training  Maintain current CV and credentials  Thoroughly understand and comply with the protocol  Comply with applicable regulations/GCP guidelines  Follow your institution’s HIPAA requirement policies  Permit monitoring by sponsors and their representatives 17

 Provide and document protocol, GCP/regulatory training  Maintain a delegation of responsibilities log  Maintain training records/log  Maintain screening and enrollment logs  Maintain subject code list  Maintain monitoring visit log  Create and maintain an investigator binder to store documentation and records 18

19

When designing and developing a study protocol, consider:  Time needed for the development of: ◦ the protocol and consent document ◦ additional documents such as the Manual of Procedures and Case Report Forms/Data Collection Tools  Recruitment and enrollment strategies for study population  Necessary time commitments for all investigators 20

 Adequate ancillary staff support  Proper training of research staff  Available facilities and space  Time required for review of these items by NIDCR and the IRB 21

 Document investigators’ agreement to follow the protocol ◦ NIDCR protocol template has sign-off page  Adhere to the IRB-approved protocol/protocol amendments  Only deviate from the protocol to avoid immediate hazards to subjects  Document and report all protocol deviations to the IRB 22

 Review protocol for reporting requirements  Notify subjects of care needed and provide referral  Actively monitor, ensure care for, and document AEs  Follow to resolution  Report AEs to the IRB/Safety Committee and comply with any specific guidance 23

 Review protocol for reporting requirements  Train study team members on UP definition  Report UPs to the IRB/other oversight bodies specified by the protocol, and comply with any specific guidance  Actively monitor, ensure care for, and document UPs  Follow to resolution 24

25

 Permits evaluation of the conduct of a study  Permits evaluation of data collected  Demonstrates GCP and compliance with applicable regulatory requirements  Facilitates study management and oversight  Allows for monitoring and evaluation of practices 26

 IRB-approved protocols, consents, advertisements  IRB correspondence/approval letters  CVs/credentials for investigators  Staff training logs/records  Delegation of Responsibilities log  Screening/enrollment logs  Subject ID code lists  Signed consent documents and data collection forms  Monitoring visit log/visit reports 27

 The Clinical Site Monitoring Plan will include: ◦ Site Assessment ◦ Site Initiation Meeting ◦ Interim Monitoring Visits ◦ Close-out Visit  Other monitoring may include: ◦ Core lab ◦ Data Coordinating Center / Data Management Center 28

 Describe how data will be collected and maintained ◦ Development of a Data Management Plan ◦ Development of a source document management process  Develop Case Report Forms (CRFs) or appropriate data collection tools  Maintain source documentation  Record data on study forms in a timely manner ◦ Examples include interview forms, questionnaires, data collection forms, research chart (paper or electronic format) 29

 Ensure data is accurate, complete and legible  Data corrections should not obscure original entries  Implement data quality control procedures 30

 Includes (but is not limited to) collection, labeling, processing, storage, shipment, and tracking of specimens  Handling in accordance with the requirements of the protocol, MOP, IRB, and applicable regulations  Tracking of final disposition of samples at end of study 31

 45 CFR 46 & ICH E6 GCP Provides Guidance and Standards for: ◦ Rights, safety, and well-being of subjects ◦ Roles and Responsibilities of Investigators and Research Staff ◦ Study conduct and protocol management ◦ Safety reporting ◦ Documentation and Record Keeping 32

33

34 ObjectiveResource Protection of human subjects45 CFR 46 Staff qualifications/trainingICH E6, Sec 4.1. Sec 4.2 Research resourcesICH E6, Sec 4.2 Protocol adherenceICH E6, Sec 4.5 Record keepingICH E6, Sec 4.4.1, Sec 4.9, Sec 8 FAQs (OHRP Investigator Responsibilities) ories/1567

Forms  NIDCR Investigator of Record Agreement  Delegation of Responsibilities Log  Training Log  Site Screening and Enrollment Log  Subject Code List  Adverse Event Forms  Monitoring Visit Log 35

Training Presentations  Investigator Responsibilities (ICH & GCP) These resources and other tools are available through NIDCR’s Toolkit for Clinical Researchers: 36